Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atropine 0.5% vs 0.05% for Myopia Progression in Children
NCT05667454Phase 3Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Dec 2022
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of NVK002 in myopia, sponsored by Erasmus MC. Started Dec 2022; status: active, not recruiting.
02
Drugs
NVK002
03
Conditions
myopia
Beyond the preview
Go deeper on NCT05667454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667454.